191 related articles for article (PubMed ID: 36918234)
1. Effects of ileocolonic delivered vitamin B
Otten AT; Peters V; Barth I; Stevens CL; Bourgonje AR; Frijlink HW; Harmsen HJM; Rehman A; Campmans-Kuijpers MJE; Dijkstra G
BMJ Open; 2023 Mar; 13(3):e069654. PubMed ID: 36918234
[TBL] [Abstract][Full Text] [Related]
2. Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of a pilot study.
Verburgt CM; Dunn KA; Otley A; Heyman MB; Verstraete S; Sunseri W; Sylvester F; de Meij T; Comeau A; Langille M; de Jonge WJ; Benninga MA; Van Limbergen JE
BMJ Open; 2023 Feb; 13(2):e064944. PubMed ID: 36725090
[TBL] [Abstract][Full Text] [Related]
3. Crohn's disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial.
Raman M; Ma C; Taylor LM; Dieleman LA; Gkoutos GV; Vallance JK; McCoy KD; Lewis I; Jijon H; McKay DM; Mutch DM; Barkema HW; Gibson D; Rauch M; Ghosh S
BMJ Open Gastroenterol; 2022 Jan; 9(1):. PubMed ID: 35046093
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn's disease population: PediCRaFT Trial.
Pai N; Popov J; Hill L; Hartung E
BMJ Open; 2019 Nov; 9(11):e030120. PubMed ID: 31784432
[TBL] [Abstract][Full Text] [Related]
6. Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study.
Smits LJT; Pauwels RWM; Kievit W; de Jong DJ; de Vries AC; Hoentjen F; van der Woude CJ;
BMJ Open; 2020 May; 10(5):e035326. PubMed ID: 32461297
[TBL] [Abstract][Full Text] [Related]
7. Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial.
Janssen L; Romberg-Camps M; van Bodegraven A; Haans J; Aquarius M; Boekema P; Munnecom T; Brandts L; Joore M; Masclee A; Jonkers D; Pierik M
BMJ Open; 2021 May; 11(5):e042885. PubMed ID: 33947729
[TBL] [Abstract][Full Text] [Related]
8. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
[TBL] [Abstract][Full Text] [Related]
9. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
10. Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study.
Paulides E; Lie MRKL; van der Woude CJ
BMJ Open; 2022 Apr; 12(4):e058358. PubMed ID: 35396307
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.
Langley BO; Ryan JJ; Phipps J; Buttolph L; Bray B; Aslan JE; Metz TO; Stevens JF; Bradley R
Trials; 2022 Oct; 23(1):885. PubMed ID: 36273173
[TBL] [Abstract][Full Text] [Related]
13. PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial.
Parkes M; Noor NM; Dowling F; Leung H; Bond S; Whitehead L; Upponi S; Kinnon P; Sandham AP; Lyons PA; McKinney EF; Smith KGC; Lee JC
BMJ Open; 2018 Dec; 8(12):e026767. PubMed ID: 30523133
[TBL] [Abstract][Full Text] [Related]
14. Capsules with Ileocolonic-Targeted Release of Vitamin B
Ahmed AA; Otten AT; Gareb B; Huijmans JE; Eissens AC; Rehman A; Dijkstra G; Kosterink JGW; Frijlink HW; Schellekens RCA
Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242596
[TBL] [Abstract][Full Text] [Related]
15. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
16. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
Papamichael K; Jairath V; Zou G; Cohen B; Ritter T; Sands B; Siegel C; Valentine J; Smith M; Vande Casteele N; Dubinsky M; Cheifetz A
BMJ Open; 2022 Apr; 12(4):e057656. PubMed ID: 35365535
[TBL] [Abstract][Full Text] [Related]
17. Effect of faecal calprotectin testing on referrals for children with chronic gastrointestinal symptoms in primary care: study protocol for a cluster randomised controlled trial.
Ansems S; Berger M; Rheenen PV; Vermeulen K; Beugel G; Couwenberg M; Holtman G
BMJ Open; 2021 Jul; 11(7):e045444. PubMed ID: 34301652
[TBL] [Abstract][Full Text] [Related]
18. Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID).
Campmans-Kuijpers MJE; Dijkstra G
Nutrients; 2021 Mar; 13(4):. PubMed ID: 33806061
[TBL] [Abstract][Full Text] [Related]
19. Effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson's disease (the MEDI-PD study): study protocol for a randomised controlled trial.
Rusch C; Beke M; Tucciarone L; Dixon K; Nieves C; Mai V; Stiep T; Tholanikunnel T; Ramirez-Zamora A; Hess CW; Langkamp-Henken B
BMJ Open; 2021 Sep; 11(9):e053336. PubMed ID: 34551955
[TBL] [Abstract][Full Text] [Related]
20. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
